55 completed, 13 unknown, 9 terminated, 7 recruiting. 94 Phase 1, 20 Phase 2.
Follow Chronic Hepatitis B: new trials by email Literature Review of Chronic Hepatitis B trials Research Report on Chronic Hepatitis B
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, Placebo, TVAX-008 - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Ausper Biopharma Co., Ltd. | 105 | 2026-10-31 | 2026-10-19 |
| A Study of Sequential Therapy With AHB-137 Injection Followed by TVAX-008 Injection in Participants Living With Chronic Hepatitis B (CHB) AHB-137, TVAX-008, Placebo - Chronic Hepatitis B | Phase 1 / Phase 2 | Not yet recruiting | Grand Theravac Life Sciences (Hangzhou) Co., Ltd. | 105 | 2026-10-31 | 2026-10-27 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Characteristics of ACT500 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Complicated With Chronic Hepatitis B ACT500 Tablets, ACT500 Placebo Tablets - Metabolic Dysfunction-associated Steatotic Liver Disease, Chronic Hepatitis b | Phase 1 | Not yet recruiting | Xiamen Amoytop Biotech Co., Ltd. | 24 | 2026-10-30 | 2026-09-14 |
| A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function. AHB-137 injection - Chronic Hepatitis B | Phase 1 | Recruiting | Ausper Biopharma Co., Ltd. | 32 | 2026-07-09 | 2026-07-29 |
| A Phase I Clinical Trial of CPU-YL01 Injection in Patients With Chronic Hepatitis B. CPU-YL01 Injection Intramuscular administration, Placebo intramuscular injection - Chronic Hepatitis B | Phase 1 | Enrolling by invitation | Jiangsu Chuangyuan Life Science and Technology Co., Ltd. | 74 | 2026-07-03 | 2026-11-05 |
| A Randomised Controlled Phase 1 Study of Vaccine Therapy for Control or Cure of Chronic Hepatitis B Virus Infection Therapeutic hepatitis B vaccine, Commercial Hepatitis B vaccine - Chronic Hepatitis b | Phase 1 / Phase 2 | Not yet recruiting | Vaxine Pty Ltd | 40 | 2026-03-01 | 2025-09-22 |
| SA1211 Injection Phase 1 Study SA1211 injection, SA1211 injection placebo - Chronic Hepatitis B | Phase 1 | Recruiting | Suzhou Siran Biotechnology Co.,Ltd. | 80 | 2025-11-25 | 2025-12-10 |
| TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B Hepatitis B Vaccine Recombinant, Adjuvanted Intramuscular Solution [HEPLISAV-B] - Hepatitis B, Chronic Hepatitis B | Phase 1 | Recruiting | University of Maryland, Baltimore | 10 | 2025-10-16 | 2025-10-20 |
| TherVacB - A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate TherVacB (HEPLISAV B +/- HBcoreAg + MVA-HBVac), TherVacB (2xHEPLISAV B + HBcoreAg + MVA-HBVac) - Chronic Hepatitis B | Phase 1 / Phase 2 | Recruiting | Michael Hoelscher | 81 | 2025-06-12 | 2026-06-11 |
| A Study to Evaluate the Safety and Immunogenicity of an Investigational Vaccine for Chronic Hepatitis B Virus Infection, in Healthy Adults AVX70371, Placebo - Chronic Hepatitis b | Phase 1 | Completed | AstriVax Therapeutics | 16 | 2025-05-06 | 2026-10-08 |
| HBV-Specific TCR-T Cell Therapy Combined With Nucleos(t)Ide Analogues in Chronic Hepatitis B Patients LioCyx-M - Chronic Hepatitis b | Phase 1 | Recruiting | Changhai Hospital | 19 | 2024-12-31 | 2025-07-17 |
| A Clinical Study of HT-101 and/or HT-102 in Patients With Chronic Hepatitis B Virus Infection HT-101, HT-102 - Chronic Hepatitis B | Phase 1 / Phase 2 | Active not recruiting | Suzhou HepaThera Biotech Co., Ltd. | 86 | 2024-12-30 | 2026-10-29 |
| Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients EPI-003 - Chronic Hepatitis B, HBV (Hepatitis B Virus) | Phase 1 | Not yet recruiting | Epigenic Therapeutics, Inc | 36 | 2024-12-01 | 2024-10-28 |
| Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B Tune-401 - Chronic Hep B, Chronic Hepatitis b | Phase 1 | Recruiting | Tune Therapeutics, Inc. | 36 | 2024-11-29 | 2026-01-06 |
| A Phase I, the Study to Evaluate the Safety, Immunogenicity and Efficacy of YS-HBV-002 YS-HBV-002 - Chronic Hepatitis B | Phase 1 | Terminated | Yisheng Biopharma (Singapore) Pte. Ltd. | 16 | 2024-07-01 | 2025-02-24 |
| A Study of BW-20507 in Chinese Healthy Subjects and Subjects With Chronic Hepatitis B Placebo, BW-20507 - Chronic Hepatitis B | Phase 1 | Completed | Shanghai Argo Biopharmaceutical Co., Ltd. | 32 | 2024-06-24 | 2026-07-31 |
| A Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of ABI-4334 in Subjects With Chronic Hepatitis B Virus Infection ABI-4334, Placebo - Chronic Hepatitis B | Phase 1 | Completed | Assembly Biosciences | 20 | 2024-06-04 | 2025-07-23 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CB06-036 in Subjects With Chronic Hepatitis B CB06-036, Placebo - Chronic Hepatitis b | Phase 1 | Completed | Shanghai Zhimeng Biopharma, Inc. | 30 | 2024-04-22 | 2025-05-21 |
| A Heterologous Protein Prime/MVA Boost Therapeutic Hepatitis B Vaccine Candidate HEPLISAV B; TherVacB, TherVacB - Chronic Hepatitis B | Phase 1 | Completed | Universitätsklinikum Hamburg-Eppendorf | 26 | 2024-01-23 | 2026-06-04 |
| A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B Placebo, TQA3605 tablets, Entecavir dispersible tablets - Chronic Hepatitis b | Phase 1 / Phase 2 | Active not recruiting | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 88 | 2023-12-07 | 2024-11-14 |
Showing 20 of 94. Sign in to see all of them.
Hepatitis B, Chronic (94) · Hepatitis B (21) · Bronchiolitis Obliterans Syndrome (3) · Hepatitis (2) · Hepatitis, Chronic (2) · Liver Diseases (1) · Virus Diseases (1)
Blood-Borne Infections (94) · Chronic Disease (94) · Communicable Diseases (94) · DNA Virus Infections (94) · Digestive System Diseases (94) · Disease Attributes (94) · Hepadnaviridae Infections (94) · Hepatitis, Viral, Human (94) · Infections (94) · Pathologic Processes (94) · Pathological Conditions, Signs and Symptoms (94) · Liver Diseases (93) · Virus Diseases (93) · Hepatitis (92) · Hepatitis, Chronic (92)
entecavir (9) · Tenofovir (8) · peginterferon alfa-2a (8) · NVR 3-778 (3) · tenofovir alafenamide (3) · Engerix-B (2) · Heplisav-B (2) · Midazolam (2) · Ritonavir (2) · Telbivudine (2) · ((1-((2-amino-9H-purin-9-yl)methyl)cyclopropyl)oxy)methylphosphonic acid dipivoxyl (1) · APG-1387 (1) · Digoxin (1) · Drug and Narcotic Control (1) · Esomeprazole (1)
Assembly Biosciences (10) · Aligos Therapeutics (4) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (3) · Chong Kun Dang Pharmaceutical (3) · Jiangsu HengRui Medicine Co., Ltd. (3) · Suzhou HepaThera Biotech Co., Ltd. (3) · Alios Biopharma Inc. (2) · Ausper Biopharma Co., Ltd. (2) · Beijing 302 Hospital (2) · Gilead Sciences (2) · Guangzhou Yipinhong Pharmaceutical CO.,LTD (2) · Hoffmann-La Roche (2) · Novartis Pharmaceuticals (2) · Novira Therapeutics, Inc. (2) · Qilu Pharmaceutical Co., Ltd. (2)
China (38) · New Zealand (27) · Hong Kong (16) · South Korea (16) · United States (11) · Australia (10) · Taiwan (9) · Moldova (8) · United Kingdom (8) · Singapore (7) · Thailand (6) · Germany (5) · France (4) · Romania (4) · Belgium (2)
Guiqiang Wang (2) · Yan Wang (2) · Chao-Wei Hsu (1) · Chau-Ting Yeh (1) · Chin Kim (1) · Ching-Lung Lai, Dr (1) · Chongyuan Xu, MD, PhD (1) · Christophe Hezode (1) · Dave Sprengers, MD, PhD (1) · Ed Gane (1) · Edward Gane (1) · Fu-Sheng Wang, M.D. (1)
PMID 30625297, PMID 37290591, PMID 16310901, PMID 20090916, PMID 20091678, PMID 23774433, PMID 24394187, PMID 24555998, PMID 24995515, PMID 30088198, PMID 31711752, PMID 34037271, PMID 34280012, PMID 34741731, PMID 35040959, PMID 35485346, PMID 39389081, PMID 39815989, PMID 40882923, PMID 41268712, PMID 41554267, PMID 42214405
2009 (1), 2017 (1), 2019 (1), 2025 (1)